Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy

키워드

참고문헌 (125)

1. Ma Y, "Chemotherapy and radiotherapy: cryptic anticancer vaccines", Semin Immunol, 22, pp.113~124 (2010)
2. Zhou J, "Advances and prospects in cancer immunotherapy", New J Sci, 2014, pp.745808~ (2014)
3. Kimura H, "Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer", Cancer Immunol Immunother, 64, pp.51~59 (2015)
4. Virani NA, "Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer", Cancer Lett, 425, pp.174~182 (2018)
5. Devaud C, "Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy", OncoImmunology, 2, pp.e25961~ (2013)
6. Drake CG, "Combination immunotherapy approaches", Ann Oncol, 23(Suppl 8), pp.viii41~viii46 (2012)
7. Schindler U, "AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy", Eur J Cancer, 92(Suppl 1), pp.S14~S15 (2018)
8. Balkwill F, "Inflammation and cancer: back to Virchow", Lancet, 357, pp.539~545 (2001)
9. Stewart TJ, "Improving cancer immunotherapy by targeting tumor-induced immune suppression", Cancer Metastasis Rev, 30, pp.125~140 (2011)
10. Whiteside TL, "The tumor microenvironment and its role in promoting tumor growth", Oncogene, 27, pp.5904~5912 (2008)
11. Mao FY, "Increased tumor-infiltrating CD45RA−CCR7− regulatory T-cell subset with immunosuppressive properties foster gastric cancer progress", Cell Death Dis, 8, pp.e3002~ (2017)
12. Zamarron BF, "Dual roles of immune cells and their factors in cancer development and progression", Int J Biol Sci, 7, pp.651~658 (2011)
13. Mao L, "Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma", J Cell Mol Med, 21, pp.2199~2210 (2017)
14. Trikha P, "Signaling pathways involved in MDSC regulation", Biochim Biophys Acta, 1846, pp.55~65 (2014)
15. Tanaka T, "Frequency of myeloid-derived suppressor cells in the peripheral blood reflects the status of tumor recurrence", Anticancer Res, 37, pp.3863~3869 (2017)
16. Young A, "Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses", Cancer Cell, 30, pp.391~403 (2016)
17. Iannone R, "Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma", Neoplasia, 15, pp.1400~1409 (2013)
18. Sun X, "CD39", ENTPD1expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice, 2010, pp.139, 1030~1040
19. Wang X, "Tumor CD73", A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma:correlations with clinicopathological characteristics and clinical outcome, 2019, pp.145, 1414~1422
20. Perrot I, "Blocking antibodies targeting the CD39", CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies, 2019, pp.27, 2411~2425.e9
21. Bours MJ, "Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation", Pharmacol Ther, 112, pp.358~404 (2006)
22. Fredholm BB, "Adenosine, an endogenous distress signal, modulates tissue damage and repair", Cell Death Differ, 14, pp.1315~1323 (2007)
23. Haskó G, "Adenosine: an endogenous regulator of innate immunity", Trends Immunol, 25, pp.33~39 (2004)
24. Haskó G, "Adenosine receptors: therapeutic aspects for inflammatory and immune diseases", Nat Rev Drug Discov, 7, pp.759~770 (2008)
25. Sitkovsky M, "Adenosine A2A receptor antagonists:blockade of adenosinergic effects and T regulatory cells", Br J Pharmacol, 153(Suppl 1), pp.S457~S464 (2008)
26. Zarek PE, "A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells", Blood, 111, pp.251~259 (2008)
27. Borsellino G, "Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression", Blood, 110, pp.1225~1232 (2007)
28. Ohta A, "The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway", Front Immunol, 3, pp.190~ (2012)
29. Sundström P, "Regulatory T cells from colon cancer patients inhibit effector T-cell migration through an adenosine-dependent mechanism", Cancer Immunol Res, 4, pp.183~193 (2016)
30. Di Gennaro P, "T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients", Cancer Lett, 417, pp.124~130 (2018)
31. Turtle CJ, "Dendritic cells in tumor immunology and immunotherapy", Curr Drug Targets, 5, pp.17~39 (2004)
32. Schnurr M, "Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells", Blood, 103, pp.1391~1397 (2004)
33. Panther E, "Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells", Blood, 101, pp.3985~3990 (2003)
34. Novitskiy SV, "Adenosine receptors in regulation of dendritic cell differentiation and function", Blood, 112, pp.1822~1831 (2008)
35. Challier J, "Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8+ T-cell priming capacity", Immunology, 138, pp.402~410 (2013)
36. Gabrilovich DI, "Myeloid-derived suppressor cells as regulators of the immune system", Nat Rev Immunol, 9, pp.162~174 (2009)
37. Watanabe S, "Tumor-induced CD11b+Gr-1+myeloid cells suppress T cell sensitization in tumor-draining lymph nodes", J Immunol, 181, pp.3291~3300 (2008)
38. Ryzhov S, "Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells", J Immunol, 187, pp.6120~6129 (2011)
39. Ryzhov SV, "Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors", J Immunol, 193, pp.3155~3164 (2014)
40. Sorrentino C, "Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model", Oncotarget, 6, pp.27478~27489 (2015)
41. Raskovalova T, "Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells", J Immunol, 175, pp.4383~4391 (2005)
42. Raskovalova T, "Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells", J Immunol, 175, pp.4383~4391 (2005)
43. Beavis PA, "Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors", Proc Natl Acad Sci U S A, 110, pp.14711~14716 (2013)
44. Hatfield SM, "Immunological mechanisms of the antitumor effects of supplemental oxygenation", Sci Transl Med, 7(277ra30) (2015)
45. Morandi F, "CD56brightCD16− NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation", J Immunol, 195, pp.965~972 (2015)
46. Nowak M, "The A2aR adenosine receptor controls cytokine production in iNKT cells", Eur J Immunol, 40, pp.682~687 (2010)
47. reckler LM, "Adenosine inhibits tumor necrosis factor-α release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor", J Pharmacol Exp Ther, 317, pp.172~180 (2006)
48. Haskó G, "Regulation of macrophage function by adenosine", Arterioscler Thromb Vasc Biol, 32, pp.865~869 (2012)
49. Ernens I, "Adenosine up-regulates vascular endothelial growth factor in human macrophages", Biochem Biophys Res Commun, 392, pp.351~356 (2010)
50. Cekic C, "Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment", Cancer Res, 74, pp.7250~7259 (2014)
51. Cronstein BN, "Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells", J Clin Invest, 78, pp.760~770 (1986)
52. Sullivan GW, "Activation of A2A adenosine receptors inhibits expression of α4", β1 integrin (very late antigen-4) on stimulated human neutrophils, 2004, pp.75, 127~134
53. Cronstein BN, "Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors", J Immunol, 148, pp.2201~2206 (1992)
54. Taylor PR, "Macrophage receptors and immune recognition", Annu Rev Immunol, 23, pp.901~944 (2005)
55. Haskó G, "Regulation of inflammation by adenosine", Front Immunol, 4, pp.85~ (2013)
56. Barletta KE, "Regulation of neutrophil function by adenosine", Arterioscler Thromb Vasc Biol, 32, pp.856~864 (2012)
57. Allard D, "CD73-adenosine: a next-generation target in immuno-oncology", Immunotherapy, 8, pp.145~163 (2016)
58. Allard B, "Immunosuppressive activities of adenosine in cancer", Curr Opin Pharmacol, 29, pp.7~16 (2016)
59. Hatfield SM, "Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection", J Mol Med (Berl), 92, pp.1283~1292 (2014)
60. Yang M, "HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia", Immunol Cell Biol, 88, pp.165~171 (2010)
61. Li J, "CD39", CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer, 2017, pp.6, e1320011~
62. Sitkovsky MV, "Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors", Annu Rev Immunol, 22, pp.657~682 (2004)
63. Jin D, "CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression", Cancer Res, 70, pp.2245~2255 (2010)
64. Wang H, "NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity", Br J Cancer, 106, pp.1446~1452 (2012)
65. Yang Q, "Overexpression of CD73 in prostate cancer is associated with lymph node metastasis", Pathol Oncol Res, 19, pp.811~814 (2013)
66. Stagg J, "Anti-CD73antibody therapy inhibits breast tumor growth and metastasis", Proc Natl Acad Sci U S A, 107, pp.1547~1552 (2010)
67. Liu N, "CD73 as a novel prognostic biomarker for human colorectal cancer", J Surg Oncol, 106, pp.918~919 (2012)
68. Ren ZH, "CD73 is associated with poor prognosis in HNSCC", Oncotarget, 7, pp.61690~61702 (2016)
69. Ma SR, "Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma", Mol Cancer, 16, pp.99~ (2017)
70. Zhao SX, "Characteristics and clinical significance of CD73 expression in subtypes of leukemia", Zhongguo Shi Yan Xue Ye Xue Za Zhi, 19, pp.1141~1144 (2011)
71. Sciarra A, "CD73 expression in normal and pathological human hepatobiliopancreatic tissues", Cancer Immunol Immunother, 68, pp.467~478 (2019)
72. Quezada C, "5′-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells", J Cell Physiol, 228, pp.602~608 (2013)
73. Loi S, "CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer", Proc Natl Acad Sci U S A, 110, pp.11091~11096 (2013)
74. Stagg J, "CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis", Cancer Res, 71, pp.2892~2900 (2011)
75. Bartel DP, "MicroRNAs: genomics, biogenesis, mechanism, and function", Cell, 116, pp.281~297 (2004)
76. Xie M, "MicroRNA-30a regulates cell proliferation and tumor growth of colorectal cancer by targeting CD73", BMC Cancer, 17, pp.305~ (2017)
77. Wang L, "Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells", J Cancer Res Clin Oncol, 134, pp.365~372 (2008)
78. Sadej R, "Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma", Melanoma Res, 16, pp.213~222 (2006)
79. Kondo T, "Expression of CD73 and its ecto-5′-nucleotidase activity are elevated in papillary thyroid carcinomas", Histopathology, 48, pp.612~614 (2006)
80. Young A, "Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis", Cancer Res, 77, pp.4684~4696 (2017)
81. Zhou P, "Overexpression of Ecto-5′-Nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix", Cancer Biol Ther, 6, pp.426~431 (2007)
82. Zhi X, "RNA interference of ecto-5′-nucleotidase (CD73)inhibits human breast cancer cell growth and invasion", Clin Exp Metastasis, 24, pp.439~448 (2007)
83. Allard B, "Anti-CD73 therapy impairs tumor angiogenesis", Int J Cancer, 134, pp.1466~1473 (2014)
84. Auchampach JA, "Adenosine receptors and angiogenesis", Circ Res, 101, pp.1075~1077 (2007)
85. Koszałka P, "Specific activation of A3, A2A and A1 adenosine receptors in CD73-knockout mice affects B16F10 melanoma growth, neovascularization, angiogenesis and macrophage infiltration", PLoS One, 11, pp.e0151420~ (2016)
86. Merighi S, "A2B and A3adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin", Neoplasia, 11, pp.1064~1073 (2009)
87. Goepfert C, "Disordered cellular migration and angiogenesis in cd39-null mice", Circulation, 104, pp.3109~3115 (2001)
88. Poggi A, "How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive", Front Immunol, 9, pp.262~ (2018)
89. Kerkelä E, "Adenosinergic immunosuppression by human mesenchymal stromal cells requires cooperation with T cells", Stem Cells, 34, pp.781~790 (2016)
90. de Lourdes Mora-García M, "Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions", J Transl Med, 14, pp.302~ (2016)
91. Schuler PJ, "Adenosine metabolism of human mesenchymal stromal cells isolated from patients with head and neck squamous cell carcinoma", Immunobiology, 222, pp.66~74 (2017)
92. Scott AM, "Monoclonal antibodies in cancer therapy", Cancer Immun, 12, pp.14~ (2012)
93. Terp MG, "Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells", J Immunol, 191, pp.4165~4173 (2013)
94. Hay CM, "Targeting CD73 in the tumor microenvironment with MEDI9447", OncoImmunology, 5, pp.e1208875~ (2016)
95. Jacobson KA, "Adenosine receptors as therapeutic targets", Nat Rev Drug Discov, 5, pp.247~264 (2006)
96. Preti D, "History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents", Med Res Rev, 35, pp.790~848 (2015)
97. Ohta A, "A2A adenosine receptor protects tumors from antitumor T cells", Proc Natl Acad Sci U S A, 103, pp.13132~13137 (2006)
98. Cekic C, "Adenosine A2B receptor blockade slows growth of bladder and breast tumors", J Immunol, 188, pp.198~205 (2012)
99. Ryzhov S, "Host A2B adenosine receptors promote carcinoma growth", Neoplasia, 10, pp.987~995 (2008)
100. Forte G, "Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma", J Immunol, 189, pp.2226~2233 (2012)
101. Yegutkin GG, "Altered purinergic signaling in CD73-deficient mice inhibits tumor progression", Eur J Immunol, 41, pp.1231~1241 (2011)
102. Zhou X, "Effects of ecto-5′-nucleotidase on human breast cancer cell growth in vitro and in vivo", Oncol Rep, 17, pp.1341~1346 (2007)
103. Wang L, "CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice", J Clin Invest, 121, pp.2371~2382 (2011)
104. Koszałka P, "Inhibition of CD73 stimulates the migration and invasion of B16F10 melanoma cells in vitro, but results in impaired angiogenesis and reduced melanoma growth in vivo", Oncol Rep, 31, pp.819~827 (2014)
105. Azambuja JH, "CD73 downregulation decreases in vitro and in vivo glioblastoma growth", Mol Neurobiol, 56, pp.3260~3279 (2019)
106. Chakraborty C, "Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine", Mol Ther Nucleic Acids, 8, pp.132~143 (2017)
107. Zhi X, "RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells", Cancer Sci, 101, pp.2561~2569 (2010)
108. Jadidi-Niaragh F, "ownregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles", Tumour Biol, 37, pp.8403~8412 (2016)
109. Baxevanis CN, "Cancer immunotherapy", Crit Rev Clin Lab Sci, 46, pp.167~189 (2009)
110. Facciabene A, "T-regulatory cells: key players in tumor immune escape and angiogenesis", Cancer Res, 72, pp.2162~2171 (2012)
111. Lukashev D, "From “Hellstrom Paradox” to anti-adenosinergic cancer immunotherapy", Purinergic Signal, 3, pp.129~134 (2007)
112. Zhang B, "Opportunities and challenges for anti-CD73 cancer therapy", Immunotherapy, 4, pp.861~865 (2012)
113. Houot R, "T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition", Cancer Immunol Res, 3, pp.1115~1122 (2015)
114. Kalaitsidou M, "CAR T-cell therapy: toxicity and the relevance of preclinical models", Immunotherapy, 7, pp.487~497 (2015)
115. Magee MS, "Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer", Discov Med, 18, pp.265~271 (2014)
116. Beavis PA, "Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy", J Clin Invest, 127, pp.929~941 (2017)
117. Palucka K, "Cancer immunotherapy via dendritic cells", Nat Rev Cancer, 12, pp.265~277 (2012)
118. Arab S, "Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor", Tumour Biol, 39, pp.1010428317695021~ (2017)
119. Jadidi-Niaragh F, "CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice", J Control Release, 246, pp.46~59 (2017)
120. Kheshtchin N, "Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer", Cancer Immunol Immunother, 65, pp.1159~1167 (2016)
121. "Trial of PBF-509 and PDR001 in patients with advanced non-small cell lung cancer (NSCLC) (AdenONCO)"[URL]
122. "Phase 1/1b study to evaluate the safety and tolerability of CPI-444alone and in combination with atezolizumab in advanced cancers"[URL]
123. "A phase 1 clinical study of AZD4635 in patients with advanced solid malignancies"[URL]
124. "MEDI9447 alone and in combination with MEDI4736 in adult subjects with select advanced solid tumors"[URL]
125. "CPI-006 alone and in combination with CPI-444 and with pembrolizumab for patients with advanced cancers"[URL]

관련 논문AI추천